Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Appoints Maggie A. Pax to Board of Directors
March 19, 2024 07:30 ET | Repligen Corporation
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax....
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024 07:30 ET | Repligen Corporation
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 ...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
February 07, 2024 07:30 ET | Repligen Corporation
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21,...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 07:30 ET | Repligen Corporation
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
December 07, 2023 07:30 ET | Repligen Corporation
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
November 14, 2023 14:01 ET | Repligen Corporation
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation to Present at Upcoming Investor Conferences
November 07, 2023 07:30 ET | Repligen Corporation
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
November 02, 2023 07:30 ET | Repligen Corporation
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
October 31, 2023 07:30 ET | Repligen Corporation
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Third Quarter 2023 Financial Results
October 17, 2023 07:30 ET | Repligen Corporation
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31,...